Tuesday, October 22, 2019

Healthcare Electronic Data Interchange (EDI) Market Scenario Highlighting Major Drivers & Trends, 2023, says MRFR

Healthcare Electronic Data Interchange (EDI) Market Synopsis
Market Research Future (MRFR) asserts that the global healthcare electronic data interchange (EDI) market is slated to register 8.8% CAGR during the forecast period (2018-2023). The growing need to curb healthcare costs is predicted to drive the market growth globally. Electronic data interchange is referred to as a concept of electronic business communication which enables the interchange of computer-processable electronic healthcare data in the form of a user-friendly format. The data can be interchanged among healthcare professionals, healthcare institutions, and patients. EDI finds applications in medical and dental patient database management, insurance and reimbursement data management, and regulatory data management and clinical trials.


Market Potential and Pitfalls
The healthcare electronic data interchange is gradually stealing the limelight with its augmenting adoption for performance management and operational intelligence. EDI healthcare transactions enable the elimination of paper trials and digitize all the transactions which further leads to lower handling costs of the processing healthcare documents. As per the estimations of the Workgroup for Electronic Data Interchange, the healthcare players can generate savings of USD 1 per claim for health plans, USD 0.86 for hospitals, USD 1.49 for physicians, and USD 0.83 for others, with the help of EDI. Such factors are considered to create opportunities for the market growth. The market will experience a sturdy growth owing to factors such as rising demand to curb the cost of healthcare and growing support from the government for healthcare IT projects. Also, with the growing adoption of EDI software by the pharmaceutical companies, benefits associated with the adoption of EDI such as cost savings, standardization, faster processing, and improved productivity, and implementation of favorable funding policies, the market is likely to flourish.

On the contrary, concerns related to data security, the high cost of implementation of EDI software, and the hesitance to switch from conventional techniques are some of the top barriers considered to curb the market growth throughout the appraisal period. Despite such hiccups, the utilization of EDI offers affordable solutions for the medium-sized as well as small-sized healthcare providers along with improved flexibility and scalability, thereby triggering its demand across the globe.

Global Healthcare Electronic Data Interchange (EDI) Market: Segmental Analysis
The global healthcare electronic data interchange (EDI) market has been segmented on the basis of transaction, delivery mode, component, and end user.

By mode of component, the global healthcare electronic data interchange (EDI) market has been segmented into services and software. Among these, the services segment accounts for a significant share owing to the increased complexity coupled with the scale of EDI solutions as they need extensive training programs.

By mode of delivery, the global healthcare electronic data interchange (EDI) market has been segmented into EDI value-added network (VAN), web and cloud-based EDI, mobile EDI, and direct (Point-to-Point) EDI. Among these, the web & cloud-based EDI segment is considered to occupy a significant share owing to the non-requirement of software installations and low cost of web and cloud-based EDI.

By mode of transaction, the global healthcare electronic data interchange (EDI) market has been segmented into eligibility inquiry and response, claims & encounters and payment & remittance advance, claim status and response, claim attachments, referral certification and authorization, and enrollments.

By mode of end-users, the global healthcare electronic data interchange (EDI) market has been segmented into healthcare providers, healthcare payers, pharmaceutical & medical device industries, and others. Among these, the healthcare payers segment is considered to occupy the largest market share due to the increased adoption of EDI for financial management by the clinicians and physicians.

Regional Insights
Geographically, the healthcare electronic data interchange (EDI) market span across regions namely, Europe, America, Asia-Pacific, and the Middle East & Africa.

Considering the global scenario, the healthcare electronic data interchange (EDI) market is dominated by the American region due to the increasing expenditure on healthcare. With the growing participation of market players coupled with the technological advancements in the EDI software, the market is likely to flourish. For instance, PLEXIS Healthcare Systems had announced the expansion of EDI services with the formal launch of Ignite EDI back in 2016.

The European region is considered to occupy the second-largest share and is likely to retain its growth in the coming years. The growth is credited to the favorable policy implementation coupled with the rising funding from the government.

On the other hand, Asia Pacific is likely to expand at the fastest CAGR due to the surging expenditure on information technology in this region. As per the India Brand Equity Foundation, spending on IT in India is likely to reach USD 87.1 billion and rise over 9% in 2018.

Industry Updates
August 16, 2018: A leader in the healthcare technology solutions and products has recently partnered with the AWS in order to host HL7 managed services and HIPAAS healthcare EDI. They have announced to migrate the legacy workloads for their customers and also create a secure cloud-based solution on AWS for the healthcare sector.

Healthcare Electronic Data Interchange (EDI) Market Competitive Dashboard
The prominent players operating in the healthcare electronic data interchange (EDI) market comprises McKesson Corporation, ZirMed Inc., Schreiner Group, GE Healthcare, Passport Health Communications, Emdeon Inc., Siemens Healthineers, The SSI Group LLC, HealthFusion, Optum Inc., Allscripts Healthcare Solutions Inc., Cognizant, Experian Information Solutions Inc., and others.

Posted by at No comments:
Labels: ,

Monday, October 21, 2019

Infectious Disease Treatments Market to Expand at a Meteoric CAGR of 7.1% by 2023

Infectious Disease Treatments Market – Overview
The augmented frequency of infectious diseases being diagnosed globally is contributing to the rise in the development of treatments to combat it. Reports that appraise the pharmaceutical industry have been presented by Market Research Future, which creates reports on industry verticals that assess the market development and prospects. The market is foreseen to attain a CAGR of 7.1% in the course of the forecast period.

The surge in the detection of cases of acquired immunodeficiency syndrome (AIDS), hepatitis B, and tuberculosis (TB) is providing a base for the development of the infectious disease treatments market. With the presence of pathbreaking developments, in the study of treatments is expected to encourage the progress of the market further. Moreover, the rise in healthcare expenditure is expected to create a promising outlook for the growth in the forecast period.


Segmental Analysis
The segmental evaluation of the infectious disease treatments market is segmented on the basis of type, treatment, region, and end users. Based on the type, the infectious disease treatments market is segmented into bacterial diseases, viral diseases, and others. The segmentation of the infectious disease treatments market on the basis of treatment comprises of antiviral drugs, antibacterial drugs, anti-parasitic drugs, antifungal drugs, and others. On the basis of application, the infectious disease treatments market is segmented into chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, and others. Based on the end users, the infectious disease treatments market is segmented into research organization, hospitals & clinics, retail pharmacies, and others. By regions, the infectious disease treatments market is segmented into the Middle East, Europe, Africa, the Americas, and the Asia Pacific.

Detailed Regional Analysis    
The regional evaluation of the infectious disease treatments market comprises of regions such as the Middle East, Europe, Africa, Americas, and the Asia Pacific. The Americas region controls the infectious disease treatments market. A sophisticated healthcare sector and an enormous patient population afflicted with infectious diseases are driving the market growth in the Americas. Furthermore, the incidence of global players within the region is fuelling market development during the forecast period. The European region is the next major infectious disease treatments market. The presence of factors such as increased healthcare expenses, government backing for research & development, and a vast patient population is driving the European market’s progress. The Asia Pacific region is a quickly increasing region in the global market owing to the existence of constantly developing economies like India and China, which have a mounting healthcare industry. Furthermore, promising government policies like decreased excise and customs duty followed by the exceptions in service tax in India is boosting the regional market growth. On the other hand, the Middle East and African region hold the minimum share in the infectious disease treatments market owing to the incidence of underprivileged economies in the African region. Also, the low per capita income and strict government policies are restraining the market development within the African region

Competitive Analysis
The market scenario is very dependent on the factors that are shaping the opportunities and the challenges that are existing in the market. The competitors in the market are ensuring that the product and services being offered in the market are aligning with the preferences of their user base favorably. The presence of successful products and brands is shaping the development of the market to a great extent. The key success factors are also favorably contributing to the growth of the market. The fortification of the distribution channels in the market is expected to increase the penetration of the products. Also, the progress of technology has gained momentum leading to enhanced market growth. In the coming years, market profitability will progressively improve as innovation and product developments induce positive developments. The industry cost structure is also expected to alter progressively in the coming future. The innovative trends emerging in the market are expected to set grounds for robust development in the approaching period. The market size is also expected to grow significantly in the coming years.

Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K), Merck & Co., Inc. (U.S.), Sanofi (France), AstraZeneca (U.K), Mylan N.V. (U.S.), and others are some of the vital companies in the infectious disease treatments market.

Posted by at No comments:
Labels: ,

Monday, October 7, 2019

RSV Diagnostics Market: 2019 Global Industry Size, Share, Growth Opportunities, Analysis, Developments Trends, Forecast to 2023

RSV Diagnostics Market Highlights
Respiratory Syncytial Virus (RSV) is a virus that can cause serious respiratory infections such as pneumonia and bronchitis. The increasing incidence rate of respiratory infections, growing demand for in-vitro diagnostics, and growing neonatal population are major factors propelling the growth of the market. For instance, according to the Centres for Disease Control and Prevention, in the United States, RSV on an average lead to 57,527 hospitalizations among children below five years of age. On the other hand, some factor such as lack of availability of specific treatment options for RSV infections and the high number of other pathogens that cause similar symptoms of respiratory illness may hamper the growth of the market during the assessment period.


RSV Diagnostics Market Regional Analysis
The Americas is likely to dominate the global RSV diagnostics market during the forecast period. The market growth is attributed to increasing incidences of RSV infections, increasing government funding's, and increasing infant population. Additionally, growing demand for molecular diagnostics and chromatographic immunoassays in this region owing to the high accuracy, sensitivity, and specificity these devices provide. For instance, as per the data stated by the Centres for Disease Control and Prevention, in the United States, RSV leads to an estimated 2.1 million outpatient visits among children below five years of age every year. Europe is anticipated to be the second largest market in the global RSV diagnostics market. The European market is expected to grow during the forecast period owing to the growing occurrence of RSV infections and growing government funding for respiratory diseases. Asia Pacific is expected to be the fastest growing market owing to the high population base, increasing prevalence of respiratory diseases such as pneumonia and bronchitis, and growing demand for automated healthcare testing for the accurate diagnosis of diseases. Furthermore, the Middle East and Africa are expected to show the least growth in the global RSV diagnostics market. The market growth in these regions is attributed to the constantly improving healthcare infrastructure, economic development, and rising patient awareness levels.

RSV Diagnostics Market Segmentation
The global RSV diagnostics market is segmented on the basis of the product, method, and end-user. On the basis of the product, the market is classified into kits and assays, instruments, and other products. The global RSV diagnostics market on the basis of the method is segmented into molecular diagnostics, rapid antigen detection test, gel microdroplets, flow cytometry, and others. The rapid antigen detection tests are further classified into enzyme-linked immunosorbent assays, immunofluorescence assays, and other rapid antigen detection tests. Further, the other rapid antigen detection tests are classified into chromatographic immunoassays and optical immunoassays. Furthermore, on the basis of end-user, the market is segmented into hospitals and clinics, clinical laboratories, home care, and others.

Global RSV Diagnostics Key Players
Some of the key players in the global RSV diagnostics market are Quest Diagnostics, Biomerieux, Becton, Dickinson, and Company (BD), Abbott, F. Hoffman-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific, Biocartis, Luminex, Hologic, Fast Track Diagnostics, Bio-Rad Laboratories Inc., Alere, Inc., Quidel Corporation, and others.


Posted by at 1 comment:
Labels: ,

Sunday, October 6, 2019

Catheter Stabilization Device Market Report to Share Estimated Growth Rate from 2023

Catheter Stabilization Device Market Highlights:
The Global Catheter Stabilization Devices Market is expected to grow at an approximate CAGR of 7.1% during forecast period, 2018–2023. Factors such as growing demand for minimally invasive surgeries; increasing prevalence of lifestyle diseases, such as cardiovascular diseases, cancers; renal failure increase in number of surgeries which may require these devices for postoperative care; and increase in demand to reduce catheter associated complications & infections are expected to drive the market. Growing aging population contributes to increased need of catheter stabilization devices.


Catheter Stabilization Device Market Segmentation:
The Global Catheter Stabilization Devices Market is segmented based on product type, application, end user, and region.On the basis of product type, the market is segmented into Arterial Securement Devices, Central Venous Catheter Securement Devices (further sub segmented into PICC Securement Devices, Subclavian Securement Devices, Midlines Securement Devices, Femoral Securement Devices, Portal Securement Devices, Jugular Securement Devices) Peripheral Securement Devices (further sub segmented into Foley Catheter Securement Devices, Nasogastric Tubes Securement Devices,  Endotracheal Tube Securement Devices, Ventriculoperitoneal Securement Devices, Continuous Nerve Block Catheter Securement Devices) Chest Drainage Tube Securement Devices, Abdominal Drainage Tubes Securement Devices (further sub segmented into Percutaneous Endoscopic Gastrostomy Securement Devices, Jejunal Catheter Securement Devices, Umbilical Catheter Securement Devices)Epidural Securement Devices. Further, on the basis of application the market is segmented into Cardiovascular Procedures, Respiratory Procedures, Gastric and Oropharyngeal Procedures, General Surgery, Urological Procedures, Radiology and Others. End users is segmented into Hospitals & Clinics, Home Healthcare Providers and Diagnostic Centers.

Catheter Stabilization Device Market Regional Analysis:
The Global Catheter Stabilization Devices Market is segmented on the basis of regions: Americas, Europe, Asia Pacific, and the Middle East & Africa. The Americas accounted for the major share of the market owing to the huge patient population, well-developed technology, and high healthcare expenditure. Asia Pacific accounted for the second largest market, which is followed by Europe. Asia Pacific is the fastest growing catheter stabilization devices market owing to rapidly changing healthcare sector, huge patient pool in this region, and the presence of vast opportunities for the development of this market. Increasing government support for research & development, well-developed healthcare infrastructure, and presence of geriatric population have driven the European catheter stabilization devices market. However, the Middle East & Africa has the least share in the market owing to the presence of poor and slow developing countries, especially, in African region. The Middle East held the major share of the regional market due to well-developed infrastructure and high spending.

Catheter Stabilization Device Market Key players
Some of the key players in the global catheter stabilization market are 3M Company, B. Braun Melsungen Ag, Baxter International, Inc., C. R. Bard, Inc., Centurion Medical Products, Convatec, Inc M.C. Johnson Company, Inc, Medtronic PLC, Merit Medical Systems, Inc, Smiths Group PLC, TIDI Products, LLC and others.


Posted by at No comments:
Labels: ,

Friday, October 4, 2019

Atorvastatin API Market Research Report By 2024 | Global Industry Trends, Growth Rate, Size, Analysis

Atorvastatin API Market Highlights
The Global Atorvastatin API Market is estimated to be valued at USD 4,25,804.16 thousand by 2023 and is expected to register a CAGR of 3.34% during the forecast period.

The hypercholesterolemia segment is expected to lead the market and register a substantial CAGR to reach USD 2,10,753.23 thousand by the end of 2023. High prevalence of hypercholesterolemia is expected to drive the market growth. Additionally, the segment is projected to exhibit the highest CAGR of 4.09% from 2018 to 2023.
North America accounted for the largest market share of 40.64% in 2017, and the regional market is projected to register a CAGR of 3.10% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate of 5.86% during the forecast period from 2018 to 2023.


Segment Analysis
The hypercholesterolemia segment is expected to lead the market and register a substantial CAGR to reach USD 2,10,753.23 thousand by the end of 2023. High prevalence of hypercholesterolemia is expected to drive the market growth. Additionally, the segment is projected to exhibit the highest CAGR of 4.09% from 2018 to 2023.

Market Players
Market Research Future (MRFR) recognizes Teva Pharmaceutical Industries Ltd (Israel), Jubilant Life Sciences Ltd (India), Dr. Reddy’s Laboratories Ltd (India), Sun Pharmaceutical Industries Ltd (India), Ind-Swift Labs Ltd (India), Morepen Laboratories Ltd (India), Zhejiang Hisun Pharmaceutical Co Ltd (China), Anuh Pharma Ltd (India), Centrient Pharmaceuticals (The Netherlands) and Cadila Pharmaceuticals (India) as the key players in the global atorvastatin API market.

Regional Analysis
North America accounted for the largest market share of 40.64% in 2017, and the regional market is projected to register a CAGR of 3.10% during the forecast period. Asia-Pacific is expected to register the fastest CAGR. The Chinese market is projected to exhibit the highest growth rate of 5.86% during the forecast period from 2018 to 2023. 
The European market is estimated to exceed USD 1,31,094.04 thousand by 2023. High prevalence of hypercholesterolemia and mixed dyslipidemia are driving the growth of the Atorvastatin API market in the region. France is the major contributor to the growth of the regional market, followed by the UK.

Key Findings of the Study
  • The Global Atorvastatin API Market is projected to reach over USD 4,25,804.16 thousand by 2023 at 34% CAGR during the review period of 2018 to 2023.
  • North America accounted for the largest market share with the US being the major contributor to the growth of the market.
  • The hypercholesterolemia segment is projected to register the highest CAGR of 4.09% during the forecast period owing to the rising rate of hypercholesterolemia cases.
  • Key manufacturers are adopting geographic expansions, corporate acquisitions and product launches as growth strategies.

Posted by at No comments:
Labels: ,

Arrhythmia Monitoring Devices Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast to 2024

The global arrhythmia monitoring devices market is expected to grow at a strong 7% CAGR over the forecast period from 2018 to 2023, according to a new research report from Market Research Future (MRFR). The global arrhythmia monitoring devices market is mainly driven by the growing prevalence of arrhythmia and rising technological advancement in monitoring devices. The rising healthcare expenditure in emerging regions as well as developed economies is also likely to remain a major factor in the global arrhythmia monitoring devices market’s progress over the forecast period.

Arrhythmia monitoring devices are used to monitor the heartbeat of patients with arrhythmias, i.e. fluctuations in the normal rate and pattern of the heartbeat. The heart beating too slowly, too fast, or irregularly can be a sign of deeper, more serious cardiovascular problems. Thus, arrhythmia monitoring devices play an important role in diagnosing cardiovascular conditions and checking their progress. Arrhythmia monitoring devices are useful in not only tracking the heartbeat of a patient over a long period of time, but also in alerting medical authorities in cases of emergency, as rapid changes in the heartbeat patterns can only indicate heart problems. Thus, their use has become widely prevalent in medical establishments all over the world, leading to progress of the global arrhythmia monitoring devices market.


The increasing technological advancement in arrhythmia monitoring devices is likely to be a key driver for the market and a key point of contention in terms of the competition in the market. Coming up with more efficient arrhythmia monitoring devices is likely to be rewarded by success and is thus likely to be a key agenda for major players in the global arrhythmia monitoring devices market. The increasing healthcare expenditure around the world is also likely to be a major driver for the global arrhythmia monitoring devices market, as the number of monitoring devices sold in government hospitals in emerging countries is increasing rapidly. The increasing investment in private hospitals in emerging countries is thus also likely to be a major factor for the global arrhythmia monitoring devices market over the forecast period.

Segmentation:
The global arrhythmia monitoring devices market has been segmented based on device type, service providers, application, end use, and region.
On the basis of devices, the arrhythmia monitoring devices market has been classified into implantable cardiac monitors, mobile cardiac telemetry devices, resting ECG devices, ECG stress test devices, Holter monitors, and others.
On the basis of service providers, the market is segmented into mobile cardiac telemetry monitoring service providers, independent diagnostic testing facilities/clinics, others.
On the basis of application, the market has been classified as bradycardia, tachycardia, atrial fibrillation, ventricular fibrillation, premature contraction, conduction disorders, and others.
On the basis of end use, the arrhythmia monitoring devices market has been segmented into hospitals & clinics, ambulatory surgery centers, diagnostic centers, home care settings, long term care centers, emergency medical services.

Regional Analysis:
The global arrhythmia monitoring devices market is likely to be dominated by North America over the forecast period. Widespread availability of technologically advanced arrhythmia monitoring devices in North America, led by the U.S. and Canada, is the major driver for the regional segment. The growing prevalence of cardiac arrhythmias in the U.S., due to lifestyle factors such as sedentary lifestyle and excessive smoking, is likely to be a major driver for the arrhythmia monitoring devices market in the region over the forecast period.
Europe also holds a major share in the global arrhythmia monitoring devices market and is likely to remain a leading contributor due to the growing prevalence of arrhythmia in the region. According to the European Heart Network, close to 4 million deaths occur in Europe every year due to cardiovascular diseases.

Competitive Analysis:
Leading players in the global arrhythmia monitoring devices market include Cardiac Science Corporation, Koninklijke Philips, Welch Allyn, Nihon Kohden Corporation, BioTelemetry Inc., Biotronik, Abbott, Aurora Resurgence, Medi-Lynx Cardiac Monitoring, Preventice Solutions Inc., iRhythm Technologies Inc., Applied Cardiac Systems, Medtronic, AliveCor Inc., Fukuda Denshi, Spacelabs Healthcare, GE Healthcare, and NUUBO Smart Solutions Technologies.

Industry Updates:
In February 2019, CardioComm received FDA clearance for a new ECG device named HeartCheck CardiBeat.


Posted by at No comments:
Labels: ,

Thursday, October 3, 2019

Tissue Engineering Market to Reflect Significant Growth Pace by 2024

Market Research Future has Published a Cooked Research Report on the Global Tissue Engineering Market.

Market Highlights
The Global Tissue Engineering Market is estimated to be valued at USD 53,424.00 Million by 2024 and is expected to register a CAGR of 17.84% during the forecast period.

The nano-fibrous material segment dominated the global tissue engineering market, by material, and is projected to reach USD 16,235.5 Million by 2024 owing to the cost-effectiveness of the product; moreover. However, the biomimetic material segment is projected to be the fastest-growing segment during the forecast period.
North America dominated the market, accounting for the largest share of the market in 2018, and the regional market is expected to register a CAGR of 17.17% during the review period. The European market was the second largest in 2018. The market is projected to reach USD 16,514.6 million by the end of 2024.   


Segment Analysis
The global tissue engineering market has been segmented based on material, application, and region. On the basis of material, the market has been divided into nano-fibrous material, biomimetic material, composite material. The nano-fibrous material segment held the majority market share in 2018. However, the biomimetic material segment is anticipated to be the fastest-growing, followed by the composite material segment.

On the basis of application, the market has been divided into orthopedics, musculoskeletal and spine, cancer, skin/integumentary, dental, cardiology, urology, neurology, cord blood & cell banking, GI & gynecology. The orthopedics, musculoskeletal and spine segment accounted for the larger market share in 2018. However, the cancer segment is expected to exhibit higher CAGR during the forecast period.

Market Players
Market Research Future (MRFR) recognizes Stryker (US), Allergan (US), Medtronic (Ireland), Zimmer (US), Baxter International (US), Integra Life Sciences (US), Organovo Holdings Inc (US), Cook Medical (US), DePuy Synthes (US), Acelity (US) as the key players in the Global Tissue Engineering Market.

Regional Analysis
Geographically, the global tissue engineering market has been segmented into North America, Europe, Asia-Pacific, and the rest of the world. As per MRFR analysis, North America was the largest market for tissue engineering in 2018 and is expected to remain dominant during the review period. Europe accounted for a significant market share and is projected to be the second-largest market during the forecast period. The rising prevalence of chronic diseases is a major driving factor for the growth of the tissue engineering market in Europe.

Key Findings of the Study:
  • The Global Tissue Engineering Market is projected to reach over USD 53,424.00 million by 2024 at a 84% CAGR during the review period of 2019 to 2024.
  • North America accounted for the largest market share.
  • The nano-fibrous material segment is projected to register the highest CAGR of 18.08% during the forecast period.
  • Key manufacturers are adopting geographic expansions, corporate acquisitions, and product launches as growth strategies. Moreover, they are focusing on e-commerce for distribution.

Posted by at No comments:
Labels: ,

Wednesday, October 2, 2019

Veterinary CBD Market Value Chain, Factor Analysis, Region and Forecasts Till 2025

Market Overview

The Global Veterinary CBD Market is poised to register a CAGR of 129.97% during the forecast period.
This impressive CAGR is possible due to the increasing number of household pets, the rising demand for humane practices in livestock management, and the easing of restrictions governing the use of CBD products to treat various ailments.

The market for global veterinary CBD products is already very diverse with multiple channels of sale.


SEGMENTATION By Source
CBD products are derived from two principle sources. Each source produces its own strain and strength of CBD-related products and independently rank within the legal framework of nations.
  1. Marijuana-Derived: Marijuana is prized for its potent THC production but is hampered by the lack of a supporting legal framework for manufacture and processing. This is changing rapidly with marijuana being legalized in countries such as Canada and South Africa and various states in the US. Many countries are moving toward legalization the growth and sale of marijuana and are, therefore, potential markets for CBD products in the foreseeable future.
  2. Hemp-Derived: Hemp has been traditionally valued for the strength of its fiber which is used in numerous industries. With the advent of CBD products and the laws restricting marijuana production, hemp is being used as a source of THC for the production of numerous CBD items. Though it has a weaker THC count than marijuana, hemp is legal throughout the world, resulting in the larger market share for the segment.  
By Product
There is a vast array of veterinary CBD products available in the market.
  1. Food-Grade: Leading the market for global veterinary CBD products are food-grade items. This can be attributed to the increasing spending by pet owners. The US pet food market is expected to grow by 4.5% from 2018 to 2019, while the pet healthcare market is projected to reach USD 18.98 billion by 2019, growing by 4.8% from the previous year.  The segment can be further divided into:
    1. Treats: Ideal for small doses and inducing calmness
    2. Chews: Best for animals that tend to gnaw  
    3. Others: Items such as hemp capsules and hemp biscuits
  2. Therapeutic-Grade: Though the certification process for therapeutic products for animals is lengthy, the easing of restrictions on CBD products for medicinal purposes shall ensure that the segment registers the highest growth rate.
    1. Pet Supplements: CBD-infused pet supplements is a growing market increasing research on the beneficial effects of CBD in treating various mental and physiological pet afflictions.
    2. Pet CBD Oils: Used for a plethora of ailments
  3. Personal Care: These products focus on the mental health of animals, an area which has seen remarkable growth in recent years.
By Distribution Channel
The growth of the global veterinary CBD market is directly impacted by the distribution channels. The distinguishable channels are:
  1. E-Commerce: Top distribution channel for this market, it is expected to as long as THC manufacture and processing remain in the legal gray area globally.
  2. Retail Pharmacies: The primary distribution point for CBD products for household pets, with an edge over the livestock CBD market.
  3. Veterinary Clinics: The primary distribution point for the global livestock CBD market, this segment is expected to register the highest growth rate as veterinary CBD products find greater acceptance.  
  4. Others: Direct distribution from the manufacturer and mass orders for large-scale livestock farms are covered in this segment.
Key Players
  • Honest Paws (US)
  • HolistaPet (US)
  • HempMy Pet (US)
  • Canna-Pet (US)
  • Joy Organics (US)
  • Fomo Bones (US)
  • Pet Releaf (US)
  • Green Roads of Florida (US)
  • Wet Noses (US)
By Region
The global veterinary CBD market is currently concentrated in North America but there is significant untapped potential in other regions due to the increasing number of pets with a corresponding rise in spending on pets.
  • Americas
    • North America
      • US
      • Canada
    • Latin America
  • Europe
    • Western Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Western Europe
    • Eastern Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • Middle East
    • Africa

Posted by at No comments:
Labels: ,

Nanobiosensors in Healthcare Market Projected to Deliver Greater Revenues By 2024

Market Research Future has Published a Half-Cooked Research Report on the Global Nanobiosensors in Healthcare Market.

Market Highlights
The global nanobiosensors in healthcare market is expected to register 9.84% CAGR during the forecast period (2019–2024).

The nanobiosensors are advance analytical devices used to detect the chemical and biological substance and helps to understand and analyze the nature of the biological structure. nanobiosensors are the sensors that are made up of nanomaterials and have dimensions between 1 to 100 nanometers. The increasing prevalence of diabetes, advancement in monitoring systems, and raising awareness about advance nanobiosensors are expected to drive the growth of the market during the forecast period. For Instance, According to the report published by World Health Organization(WHO) in 2016, diabetes is a major healthcare concern in Brazil, and it affected more than 8.1% of the population, the prevalence of diabetes was more in females, and it affected more than 8.8% females in the country.
However, high costs involved in research and development and unwillingness toward the adoption of new treatment practices hinder the growth of the market during the forecast period.


Segmentation
The global nanobiosensors in healthcare market has been segmented on the basis of type, application, end user, and region.

On the basis of type, the market has been classified as optical nanobiosensor, electrochemical nanobiosensor, acoustic nanobiosensor, and others. The electrochemical nanobiosensor segment is expected to hold the largest market share of the nanobiosensors in healthcare market owing to its high sensitivity and real-time detection features. Based on the application, the market has been segmented into diabetes, immunoassay, cancer, pathogenic bacteria, and others. The market, by end user, has been divided into as hospitals and clinics, diagnostic centers, point of care, and others. However, based on end user point of care testing segment holds the largest market share due to low complex infrastructure and training.

Key Players
Some of the prominent key players in the global nanobiosensors in healthcare market are Abbott Point of Care, Inc., F. Hoffman-LA Roche Ltd., Medtronic Inc., Nano-Proprietary, Inc., Lifescan, Inc., Illuminex Corporation, Lifesensors, Inc., ACON Laboratories, Inc., Pharmaco-Kinesis Corporation, Bayer Healthcare AG, Bio-Rad Laboratories, Inc., Biosensors International Pte. Ltd., Sysmex Corporation.

Regional Analysis
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nanobiosensors in healthcare market in the Americas has further been segmented into North America and South America, with the North America market further classified into the US and Canada.

The European nanobiosensors in healthcare market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The nanobiosensors in healthcare market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The nanobiosensors in healthcare market in the Middle East & Africa has been segmented into the Middle East and Africa.


Posted by at No comments:
Labels: ,

Global Artificial Heart Market 2019 | Industry Analysis, Company Profiles, Key Regions, Forecast to 2024

Market Research Future has Published a Half-Cooked Research Report on the Global Artificial Heart Market.

Market Highlights
The global artificial heart market held a market value of USD 1.2 billion in 2017 and is projected to grow at a CAGR of 15.1% over the forecast period. An artificial heart is a prosthetic device that is implanted into the body to provide circulation and replace heart ventricles that are diseased or damaged

Segmentation
The global artificial heart market has been segmented into type, and end user.
By type, the market has been segmented into the heart-lung machine and mechanical heart. The mechanical heart is further segmented into total artificial hearts and ventricular assist devices (VADs). The mechanical heart segment is expected to register the highest CAGR during the forecast period due to growing demand.
On the basis of end user, the market has been segmented into Hospitals & Clinics, Specialty Centers, and others.


Key Players
Some of the prominent players in the global artificial heart market are SynCardia Systems, LLC, BiVACOR Inc., CARMAT, Cleveland Heart, Inc., ABIOMED, CryoLife, Inc., Abbott, and Thoratec Corporation.

Regional Analysis
On a regional basis, the Americas is anticipated to dominate the global artificial heart market owing to the owing to increasing geriatric population, high prevalence of various chronic diseases, and a large number of diagnostic imaging centers.

Additionally, rising demand for advanced treatment and growing healthcare expenditure is driving the growth of the market. For instance, according to the American College of Cardiology Foundation, coronary heart disease (CHD) is the leading cause of deaths attributable to CV in the US. CHD contributes to over 43.8% of death cases in the US. Additionally, in 2015, the total healthcare expenditure for CVD and stroke in the US was an estimated USD 329.7 billion. CVD and stroke accounted for 14% of total health expenditures in 2015.

Europe accounts for the second largest market and holds a healthy share in the global artificial heart market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, and flourishing medical device industry due to the presence of major market players.

Asia-Pacific is expected to be the fastest growing market, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability of favorable insurance policies.

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access, and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia is the largest market share owing to the development of the healthcare industry and the rising availability of specialty care centers.



Posted by at No comments:
Labels: ,

Tuesday, October 1, 2019

Opioid Withdrawal Treatment Market Analysis on Top Key Players, Revenue Growth and Business Development Forecast to 2025

Market Research Future has Published a Half-Cooked Research Report on the Global Opioid Withdrawal Treatment Market.

Market Highlights
The global opioid withdrawal treatment market held a market value of USD 1.8 billion in 2018 and is projected to grow at a CAGR of 10.1% over the forecast period. Opioids are drugs such as heroin, opium, morphine, codeine, and methadone that are used in cases of severe, postsurgical, or chronic pain. In some cases, usage of opioids causes addiction, and Opioid withdrawal syndrome is a life-threatening condition resulting from opioid dependence. These drugs can also cause severe health problems and sometimes even result in overdose and loss of life. Hence this opioid dependence requires treatment, which is known as opioids withdrawal treatment.

Get Free Sample of This Report @ https://www.marketresearchfuture.com/sample_request/8123

Segmentation
The global opioid withdrawal treatment market has been segmented into drug type and distribution channel.
By drug type, the market has been segmented into the nonsteroidal anti-inflammatory drugs, anti-nausea medications, analgesics, natural sleep supplements, and others.
On the basis of distribution channel, the market has been segmented into hospital pharmacy, retail pharmacies, and online stores.

Key Players
Some of the prominent players in the global opioid withdrawal treatment market are Merck & Co., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Novartis, Sanofi, Johnson & Johnson Services, F. Hoffmann-La Roche Ltd, and Bayer AG among others

Regional Analysis
On a regional basis, the Americas is anticipated to dominate the global opioid withdrawal treatment market owing to the owing to increasing geriatric population, high prevalence of various chronic diseases, and rising adoption of opioids for the management of pain.

According to the Substance Abuse and Mental Health Services Administration (SAMHSA) in the National Survey on Drug Use and Health (NSDUH), about 30.5 million Americans aged 12 or older were using illicit drugs in 2018. Additionally, rising demand for advanced treatment and growing healthcare expenditure is driving the growth of the market. For instance, according to the American College of Cardiology Foundation, coronary heart disease (CHD) is the leading cause of deaths attributable to CV in the US. CHD contributes to over 43.8% of death cases in the US. Additionally, in 2015, the total healthcare expenditure for CVD and stroke in the US was an estimated USD 329.7 billion. CVD and stroke accounted for 14% of total health expenditures in 2015.

Europe accounts for the second-largest market and holds a healthy share in the global opioid withdrawal treatment market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, and flourishing pharmaceutical industry due to the presence of major market players.

Asia-Pacific is expected to be the fastest-growing market, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability of favorable insurance policies.

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access, and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia is the largest market share owing to the development of the healthcare industry and the rising availability of specialty care centers.



Posted by at No comments:
Labels: ,

Thyroid Disorder Market 2019 Global Size, Share, Growth Opportunities, Competitive Landscape, Swot Analysis By 2025

Overview:
Booming economies across the world is experiencing a radical shift to urbanization which, in a supple way, is creating a physiological disorder that is giving rise to the prevalence of various ailments. Diseases such as obesity, thyroid, autoimmune diseases are a common byproduct of this shift and trigger thyroid disorders in many which, if not checked, in time can cause severe brain damage. The global market for the thyroid disorder is expected to rise with a moderate 3.1% CAGR during the forecast period (2013-2022) and can reach up to a valuation of USD 2400.8 million in the same period. The rising cases of thyroid disorder have become a concern for many initiating a collaborative agreement between private and public organizations to spread awareness. Efforts made by the pharmacies can be considered a tactical gambit in this context. As per the report of the International Thyroid Society, near about 20 million Americans are diagnosed with some form of thyroid disease, and around 12% can get affected by it in their lifetime. Chances of contracting the disease can aggravate if the patient has diabetes.

However, the treatment incurs high cost, and alternative treatment options are on the rise which can act as a headwind for the market. Side-effects of the treatment cannot be blind sighted as well. In considering the future of the market, this can seriously cause a plummeting effect.


Industry Trend:
New research by the University of Colorado School of Medicine Department of Radiation Oncology has revealed that thyroid tumors can be treated with stereotactic body radiation therapy (SBRT). The side-effects would be far lesser than the traditional method and the treatment promises the better chance of recovery. The University of Birmingham has recently called for universal testing for thyroid function to reduce the number of miscarriages and negative neurodevelopmental effects on the baby.

Segmentation:
The global thyroid disorder market can be segmented by treatment, disease indication, route of administration and end-users.
By treatment, the market is segmented into drugs & supplements, diagnostics, and surgery.
Based on disease indication, the market includes hypothyroidism, hyperthyroidism, and others. The hypothyroidism holds the largest market share.
Based on the route of administration, the market encompasses oral, injectable, and others. High efficacy and bioavailability made the oral segment the most preferable.
On the basis of end-users, the market comprises hospitals and home use.

Regional Analysis:
Region-specific segmentation includes the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa.
The Americas are currently leading the pack with the maximum share of the market. North America is spearheading the region with a considerable number of patients and advanced technologies used in treating the disease in multiple facilities. Europe assumes the second position. However, the APAC is set to register the maximum CAGR during the forecast period as the region has two countries such as China and India which are showing considerable expansion. Market incumbents are also launching strategies to raise awareness among the populace which can further boost the sector’s revenue.

Market Competition:
The presence of several big shots across the globe is promising for the market as this will keep the market competitive and help it gain much from research and developments.
Some of the key players in this market are namely Allergan (Ireland), Abbott Laboratories (US), GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Pfizer Inc. (US), RLC LABS (US), AbbVie (US), Mylan (US)and others.




Posted by at No comments:
Labels: ,
Subscribe to: Posts (Atom)